Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
- Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform
- Biogen to pay Skyhawk potential future milestone payments and royalties
CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization.
The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research-stage therapeutic candidates for the treatment of multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders. As part of the agreement, Skyhawk received an upfront payment of $74 million from Biogen and may receive potential future milestone payments and royalties. A portion of the upfront payment will be allocated to future research services, with the remainder expensed in the first quarter of 2019 as research and development.
“Skyhawk’s platform offers a powerful approach to target neurological conditions using selective RNA-modulating small molecules, creating exciting possibilities for potential new therapies,” said Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen. “This collaboration exemplifies Biogen’s commitment to joining forces with innovative companies with the goal of improving the lives of patients living with neurological diseases.”
“Biogen is a leading neuro-focused biopharmaceutical company with a compelling history of drug development across a range of challenging neurological conditions,” said Bill Haney, co-founder and chief executive officer of Skyhawk. “Their strong scientific culture has already produced a series of leading global therapeutics. We look forward to working with their team with the goal of potentially enhancing the treatment options we could bring to the neuroscience community.”
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
About Skyhawk Therapeutics
Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTAR™ (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.
Biogen Safe Harbor Statement
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits and results that may be achieved through Biogen’s collaboration with Skyhawk; risks and uncertainties associated with drug development and commercialization; the potential of Biogen’s commercial business and pipeline programs, including potential research-stage therapeutic candidates for the treatment of MS, SMA and additional neurological disorders. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty as to whether the anticipated benefits and potential of Biogen’s collaboration with Skyhawk can be achieved; risks of unexpected costs or delays; uncertainty of success in the development and potential commercialization of potential research-stage therapeutic candidates for the treatment of MS, SMA and additional neurological disorders, which may be impacted by, among other things, the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of these drug candidates; Biogen and Skyhawk may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, or failure to protect intellectual property and other proprietary rights; product liability claims; or third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
|BIOGEN MEDIA CONTACT:
+1 617 679 4945
|BIOGEN INVESTOR CONTACT:
+1 781 464 4471
|SKYHAWK MEDIA CONTACT:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Nasdaq, Inc. Prices €600 Million Senior Notes Offering25.3.2019 20:07:00 CET | Pressemelding
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it priced a public offering of €600,000,000 aggregate principal amount of 1.75% senior notes due 2029 (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) are acting as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as oth
‘How to Sell a Massacre’ an Al Jazeera Investigation into Australia’s One Nation Party and Gun Lobby25.3.2019 18:04:00 CET | Pressemelding
Australia’s One Nation Party Lobbying the National Rifle Association of America (NRA) for Millions of Dollars One Nation’s Chief of Staff, James Ashby, hoped to secure $US20 million political donations to “own the lower house and the upper house” DOHA, Qatar, March 25, 2019 (GLOBE NEWSWIRE) -- A three-year undercover operation by Al Jazeera shows officials from the National Rifle Association of America (NRA) advising delegates from an Australian political party on how to roll back strict gun control laws and how to deal with critics following a mass shooting. Representatives from Pauline Hanson’s One Nation political party were seen seeking millions of dollars in donations from supporters of the U.S. gun lobby in Washington D.C. in order for more guns to flow into Australia. They were coached on how to react if softer gun laws ever led to a mass shooting there. An NRA media liaison officer said the organization remains silent in the immediate aftermath of a multiple shooting, but then
Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team25.3.2019 12:30:00 CET | Pressemelding
EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has appointed Mr. Adrian Marshall and Mr. James Blakelock to the joint role of Executive Vice President, Corporate Strategy and Planning, and Mr. Bill Wasson to the role of Senior Vice President, Capital Markets and Investor Relations. Working closely with Radient’s existing Management Team and Board of Directors, they will be instrumental in developing, driving and communicating the Company’s corporate strategy and global expansion. Denis Taschuk, CEO & President of Radient, commented: “These additions to our management team are very strategic in nature, and we consider ourselves fortunate to have attracted such top talent as we move forward with our global expansion plans. Both Mr. Marshall and Mr. Blakelock bring to Radient decades of experience working directly with some of the world’s leading rapid growth consu
Forterra Announces Rich Hunter as President of Drainage Pipe & Products and Vik Bhatia of Water Pipe & Products Segments25.3.2019 11:00:00 CET | Pressemelding
IRVING, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra” or the "Company”) (NASDAQ: FRTA), a leading manufacturer of water and drainage pipe and products in the United States and Eastern Canada, today announced the appointment of Rich Hunter as President of its Drainage Pipe & Products (“Drainage”) segment, and Vik Bhatia as President of its Water Pipe & Products (“Water”) segment. In their new roles, Rich and Vik will continue to report to Jeff Bradley, Chief Executive Officer. Hired as Chief Operating Officer in June 2018, Rich has successfully directed the operations team in delivering measurable improvements in cost, productivity and quality. Vik, who joined Forterra in August of 2017, has had several senior leadership roles, most recently providing focused commercial leadership in the development and execution of sales and customer service strategy for Water. Forterra CEO Jeff Bradley commented, “Rich and Vik have proven themselves as strong leaders who are bot
Nasdaq, Inc. Announces Proposed Senior Notes Offering25.3.2019 10:00:00 CET | Pressemelding
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it plans to offer, subject to market and other conditions, Euro-denominated senior notes (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) will act as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering will be made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as other documents the
cPacket Networks Acquires Solarflare’s SolarCapture Appliance Business25.3.2019 10:00:00 CET | Pressemelding
Joint Solution Provides cPacket Customers with 40Gbps Visibility into High Speed Critical Networks and Retrospective Analysis of Operational and Security Issues SAN JOSE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance monitoring and packet broker solutions, has entered into an agreement with Solarflare to acquire the company’s SolarCapture® Appliance business. Solarflare’s SolarCapture Appliance business provides network traffic capture capability for a variety of IT NetOps and SecOps applications including compliance, service-level-agreement monitoring, performance monitoring, security analytics, network forensics, and record keeping. Now an integral part of cPacket’s cStor (integrated packet-forensics for advanced real-time-analytics) product-line, the combined solution provides 100-percent lossless capture for speeds up to 40Gbps. “Making the SolarCapture Appliance technology a permanent addition to our cStor pr